Company intelligence / Profile preview

Siluxin

Jerusalem, Jerusalem District, Israeldnb.com ↗

Ownership: Private
Employees: ~14
Development stage: Other

Overview

Silexion’s first-generation LODER™ product demonstrated positive efficacy in a Phase 2 trial versus chemotherapy alone in non-resectable pancreatic cancer. The next-generation candidate, SIL204, is designed to target a broader range of KRAS mutations and has shown significant reduction of both primary tumor burden and metastatic spread in preclinical orthotopic models. The company is pursuing dual-route development strategies to address both primary tumors and metastases[1][2].

Therapeutic areas: Oncology
Modalities: Small interfering RNA (siRNA)RNA interference (RNAi)Microparticle drug deliveryTargeted drug delivery systemBiologic (for the delivery platform)
Industry: Biotech

Partnerships

Evonik Corporation – collaboration on advanced siRNA formulation development [4]

Beyond the preview

Go deeper on Siluxin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Siluxin.

Explore the full profile